Lifeboat Foundation

Adam Savage, one of the creators and hosts of the beloved show Mythbusters, collaborated with his friend Richard Browning, founder of Gravity, to demonstrate a flying, bulletproof Iron Man suit that was 3D printed from Titanium. This is a feat that has to be seen to be believed.

The creation of the suit will be featured on a new show that Savage is doing with the Science Channel. It all started when Savage visited the Colorado School of Mines and one of the engineers told him they had Titanium 3D printers, adding “if you want to print something weird, let us know.” To which Savage replied, “Really? How about a full suit of Iron Man armor?”

Circa 2020

Learn how a young team of additive manufacturing engineers helped bring 3D printed parts to the design of the GE9X, the world’s largest jet engine.

Stefka Petkova enjoys building things. It’s a passion she’s had since she was a small child when her dad, an electrician who liked to work on cars, kept the door to his workshop open. “I was exposed to that as a very young child and just got a lot of encouragement,” says Petkova, who she spent many afternoons watching him weld and wire automobiles.

Continue reading “3D Printed Engine: Bringing 3D Printing Inside The World’s Largest Jet Engine” »

Circa 2017

What is the best way to preserve music for future generations to enjoy? Store it in DNA, of course.

That is exactly what Twist Biosciences, which pioneers high-quality DNA synthesis, has facilitated in collaboration with the University of Washington and Microsoft. Two iconic performances – from the iconic Montreux Jazz Festival, one Deep Purple’s playing of Smoke on the Water, and Tutu by Miles Davis, have been ‘encoded onto DNA and read back with 100 percent accuracy.

Continue reading “Music stored in DNA” »

As of August 28th, you can now use a 3D printer to produce custom candy gummies in Berlin. The world’s first 3D candy printer, Magic Candy Factory, had been in development for over a year through German company Katjes Fassin’s UK subsidiary, and can print gummies in 3–10 minutes; competing machines take up to an hour.

This is how the future is made.

Sailing through the smooth waters of vacuum, a photon of light moves at around 300 thousand kilometers (186 thousand miles) a second. This sets a firm limit on how quickly a whisper of information can travel anywhere in the Universe.

While this law isn’t likely to ever be broken, there are features of light which don’t play by the same rules. Manipulating them won’t hasten our ability to travel to the stars, but they could help us clear the way to a whole new class of laser technology.

Continue reading “Physicists Have Broken The Speed of Light With Pulses Inside Hot Plasma” »

Europe is developing a lunar navigation and telecommunication constellation, hoping to speed up colonization of Earth’s celestial companion.

Nobody knows exactly how big the Universe actually is.

The cosmos has been expanding since the Big Bang, but how fast? The answer could reveal whether everything we thought we knew about physics is wrong.

There’s some really interesting CRISPR news out today, and it’s likely to be a forerunner of much more news to come. A research team has demonstrated what looks like robust, long-lasting effects in a primate model after one injection of the CRISPR enzymatic machinery. There have been plenty of rodent reports on various forms of CRISPR, and there are some human trials underway, but these is the first primate numbers that I’m aware of.

The gene they chose to inactivate is PCSK9, which has been a hot topic in drug discovery for some years now. It’s a target validated by several converging lines of evidence from the human population (see the “History” section of that first link). People with overactive PCSK9 have high LDL lipoproteins and cholesterol, and people with mutations that make it inactive have extremely low LDL and seem to be protected from a lot of cardiovascular disease. There are several drugs and drug candidates out there targeting the protein, as well there might be.

It’s a good proof-of-concept, then, because we know exactly what the effects of turning down the expression of active PCSK9 should look like. It’s also got the major advantage of being mostly a liver target – as I’ve mentioned several times on the blog already, many therapies aimed at gene editing or RNA manipulation have a pharmacokinetic complication. The formulations used to get such agents intact into the body (and in a form that they can penetrate cells) tend to get combed out pretty thoroughly by the liver – which after all, is (among other things) in the business of policing the bloodstream for weird, unrecognized stuff that is then targeted for demolition by hepatocytes. Your entire bloodstream goes sluicing through the liver constantly; you’re not going to able to dodge it if your therapy is out there in the circulation. It happens to our small-molecule drugs all the time: hepatic “first pass” metabolism is almost always a factor to reckon with.

The harmfulness of pesticides to beneficial organisms is one of the most serious concerns in agriculture. Therefore scientists are eagerly looking for new, more environmentally friendly and species-specific solutions. Researchers at the Estonian University of Life Sciences, Ghent and the University of Maastricht took a long step forward in this regard.

The detrimental impact of pesticides on non-target organisms is one of the most urgent concerns in current agriculture. Double-stranded RNAs (dsRNAs) represent the most species-specific class of pesticides to date, potentially allowing control of a target pest without effecting other species. The unprecedented target-specificity of dsRNA is due to its nucleotide sequence-specific mode of action that results in post-transcriptional gene silencing, or RNA interference (RNAi), in the target species. The development and field use of dsRNAs, via both the insertion of transgenes into the plant genome and the application of dsRNA sprays, is a rapidly growing area of research. Simultaneously, there exists the growing prospect of harnessing RNAi within integrated pest management schemes.

Using the pollen beetle (Brassicogethes aeneus) and its host crop oilseed rape (Brassica napus) as a model crop-pest system, a team of researchers collectively from Estonian University of Life Sciences, Ghent University and Maastricht University examined how RNAi efficacy depends on duration of dietary exposure to dsRNA. To this end, the authors applied dsRNA (specifically designed to induce RNAi in the pollen beetle) to oilseed rape flowers, and analyzed RNAi-induced mortality between insects chronically fed dsRNA and insects fed dsRNA for 3 days. Most notably, their data suggest that, with chronic dietary exposure to dsRNA, reduced dsRNA concentrations can be applied in order to achieve a similar effect compared to short-term (e.g. 3 days) exposure to higher concentrations. This observation has important implications for optimizing dsRNA spray approaches to managing crop pests.